Literature DB >> 18431253

Endothelial cell barrier impairment induced by glioblastomas and transforming growth factor beta2 involves matrix metalloproteinases and tight junction proteins.

Hideyuki Ishihara1, Hisashi Kubota, Raija L P Lindberg, David Leppert, Sergio M Gloor, Mariella Errede, Daniela Virgintino, Adriano Fontana, Yasuhiro Yonekawa, Karl Frei.   

Abstract

Gliomas, particularly glioblastoma multiforme, perturb the blood-brain barrier and cause brain edema that contributes to morbidity and mortality. The mechanisms underlying this vasogenic edema are poorly understood. We examined the effects of cocultured primary cultured human glioblastoma cells and glioma-derived growth factors on the endothelial cell tight junction proteins claudin 1, claudin 5, occludin, and zonula occludens 1 of brain-derived microvascular endothelial cells and a human umbilical vein endothelial cell line. Cocultured glioblastoma cells and glioma-derived factors (e.g. transforming growth factor beta2) enhanced the paracellular flux of endothelial cell monolayers in conjunction with downregulation of the tight junction proteins. Neutralizing anti-transforming growth factor beta2 antibodies partially restored the barrier properties in this in vitro blood-brain barrier model. The involvement of endothelial cell-derived matrix metalloproteinases (MMPs) was demonstrated by quantitative reverse-transcriptase-polymerase chain reaction analysis and by the determination of MMP activities via zymography and fluorometry in the presence or absence of the MMP inhibitor GM6001. Occludin, claudin 1, and claudin 5 were expressed in microvascular endothelial cells in nonneoplastic brain samples but were significantly reduced in anaplastic astrocytoma and glioblastoma samples. Taken together, these in vitro and in vivo results indicate that glioma-derived factors may induce MMPs and downregulate endothelial tight junction protein and, thus, play a key role in glioma-induced impairment of the blood-brain barrier.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18431253     DOI: 10.1097/NEN.0b013e31816fd622

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  35 in total

Review 1.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

Review 2.  Glioblastoma niches: from the concept to the phenotypical reality.

Authors:  Davide Schiffer; Marta Mellai; Enrica Bovio; Ilaria Bisogno; Cristina Casalone; Laura Annovazzi
Journal:  Neurol Sci       Date:  2018-05-08       Impact factor: 3.307

Review 3.  Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 4.  Gene therapy for the nervous system: challenges and new strategies.

Authors:  Casey A Maguire; Servio H Ramirez; Steven F Merkel; Miguel Sena-Esteves; Xandra O Breakefield
Journal:  Neurotherapeutics       Date:  2014-10       Impact factor: 7.620

5.  Down regulated expression of Claudin-1 and Claudin-5 and up regulation of β-catenin: association with human glioma progression.

Authors:  Hanuma K Karnati; Manas Panigrahi; Noor A Shaik; Nigel H Greig; S Appala R Bagadi; Mohammad A Kamal; Nagaiah Kapalavayi
Journal:  CNS Neurol Disord Drug Targets       Date:  2014       Impact factor: 4.388

6.  Initial contact of glioblastoma cells with existing normal brain endothelial cells strengthen the barrier function via fibroblast growth factor 2 secretion: a new in vitro blood-brain barrier model.

Authors:  Keisuke Toyoda; Kunihiko Tanaka; Shinsuke Nakagawa; Dinh Ha Duy Thuy; Kenta Ujifuku; Kensaku Kamada; Kentaro Hayashi; Takayuki Matsuo; Izumi Nagata; Masami Niwa
Journal:  Cell Mol Neurobiol       Date:  2013-02-06       Impact factor: 5.046

7.  Transforming growth factor-beta2 is a molecular determinant for site-specific melanoma metastasis in the brain.

Authors:  Chenyu Zhang; Fahao Zhang; Rachel Tsan; Isaiah J Fidler
Journal:  Cancer Res       Date:  2009-01-13       Impact factor: 12.701

8.  Cardiomyopathy in the dystrophin/utrophin-deficient mouse model of severe muscular dystrophy is characterized by dysregulation of matrix metalloproteinases.

Authors:  Dawn A Delfín; Kara E Zang; Kevin E Schill; Nikita T Patel; Paul M L Janssen; Subha V Raman; Jill A Rafael-Fortney
Journal:  Neuromuscul Disord       Date:  2012-06-29       Impact factor: 4.296

Review 9.  Targeted drug delivery to treat pain and cerebral hypoxia.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Pharmacol Rev       Date:  2013-01-23       Impact factor: 25.468

Review 10.  Glucocorticoids in the management of peritumoral brain edema: a review of molecular mechanisms.

Authors:  Roger Murayi; Prashant Chittiboina
Journal:  Childs Nerv Syst       Date:  2016-09-09       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.